Prohibiting certain insurers, nonprofit health service plans, and health maintenance organizations from imposing a step therapy or fail-first protocol for insulin or an insulin analog used to treat an insured's or enrollee's Type 1, Type 2, or gestational diabetes; and applying the Act to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after January 1, 2026.